CRBN and heart failure: Similarly, in heart failure models with reduced ejection fraction, CRBN impairs cardiac contractility by targeting Cav1.2α for CRL4ACRBN -mediated degradation, whereas TD-165 treatment improved cardiac function in both in vitro and ex vivo settings 80.